Susquehanna Fundamental Investments’s Protalix BioTherapeutics PLX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$44K	Sell	41,574 -1,326	-3%	-$1.22K	﹤0.01%	1496
2021 Q4	$36K	Sell	42,900 -16,600	-28%	-$17.4K	﹤0.01%	1383
2021 Q3	$79K	Sell	59,500 -6,600	-10%	-$10K	﹤0.01%	1637
2021 Q2	$126K	Buy	+66,100	New	+$227K	﹤0.01%	1550

Other funds holding PLX

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

SWM

Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna Fundamental Investments's PLX Position: Q1 2022 in Review

Susquehanna Fundamental Investments reduced its Protalix BioTherapeutics (PLX) stake by 3.1% in Q1 2022, selling an estimated $1.22K and leaving 41,574 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #1496.

Susquehanna Fundamental Investments first reported a position in PLX in Q2 2021 and has held it in 4 quarters since. The position peaked at $126K in Q2 2021. 32 funds tracked by Wall St. Rank hold PLX as of Q1 2022.

Susquehanna Fundamental Investments held 41,574 shares of Protalix BioTherapeutics worth $44K as of Q1 2022.
Susquehanna Fundamental Investments sold 1,326 Protalix BioTherapeutics shares in Q1 2022, an estimated $1.22K.
Protalix BioTherapeutics made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q1 2022, its #1496 holding.
Susquehanna Fundamental Investments first reported a position in Protalix BioTherapeutics in Q2 2021 and has held it in 4 quarters since.
Susquehanna Fundamental Investments's Protalix BioTherapeutics position peaked at $126K in Q2 2021.
32 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.